Clinical Assessment of New Treatment Regimen for Adult Fulminant Myocarditis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective cohort study to assess the clinical outcome of patients with fulminant myocarditis using "Life-support Based Comprehensive Treatment Regimen" and conventional therapy. In the present study, participants receive various treatment as part of routine medical care without any assignment of specific interventions to them. The process of treatment during hospitalization were recorded in medical chart and was reviewed by independent research personnel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis

NCT03219996

Viral Myocarditis Cardio-Renal Syndrome Risk Factor, Cardiovascular

COMPLETED

Myocardial Damage in COVID-19

NCT04312464

COVID-19 Cardiovascular Diseases

UNKNOWN

Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction

NCT02484326

Cardiac Rupture

COMPLETED

Risk Stratification Value of Biomarkers in Patients With Myocarditis

NCT06010199

Myocarditis

RECRUITING

The Role of Electrocardiograms in Risk Stratification and Analysis of the Characteristics of ST Elevation in Acute Myocarditis: a 2-centre Study

NCT04498494

Myocarditis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fulminant Myocarditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Life-support Based Comprehensive Treatment Regimen group

meet all the following conditions:

1. intravenous immune globulin;
2. large dose of glucocorticoids;
3. mechanical ventilation;
4. hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);
5. continuous renal replacement therapy.

No interventions assigned to this group

conventional therapy group

meet one of the following conditions:

1. without/insufficient intravenous immune globulin;
2. without/with various doses of glucocorticoid ;
3. vasoactive drug;
4. without/delayed mechanical ventilation;
5. without/delayed hemodynamic support;
6. without/delayed continuous renal replacement therapy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 16 years of age or older;
* Diagnosed as fulminant myocarditis:

* Evidence of myocarditis on biopsy or increased biomarkers of myocardial injury (TNI and CK-MB and BNP or NT-pro-BNP);
* Acute onset of symptoms of cardiac dysfunction: dyspnea, palpation, chest pain, and/or syncope;
* Image for cardiac injury: marked diffused reduction in left ventricle wall movement, with dramatically decreased left ventricle ejection fraction (LVEF) \< 45%;
* Cardiogenic shock, e.g., systolic blood pressure ≤90 mmHg or mean arterial pressure \< 70mm Hg or a systolic blood pressure decrease \> 40 mm Hg, which is associated with the signs of hypofusion: cyanosis, cold extremities, oliguria, and/or changes in mental status.

Exclusion Criteria

* Also considering acute coronary syndrome but unable to perform coronary angiography to distinguish acute coronary syndrome from fulminant myocarditis;
* Myocardial injury caused by sepsis, chemotherapeutical agents, or poisons;
* Unstable hemodynamics or shock caused by hypovolemia.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No